Effects of Melatonin Supplementation on Hormonal, Inflammatory, Genetic, and Oxidative Stress Parameters in Women With Polycystic Ovary Syndrome

• Published in: Frontiers in endocrinology (Lausanne) Vol. 10; p. 273
• Main Authors: Jamilian, Mehri, Foroozanfard, Fatemeh, Mirhosseini, Naghmeh, Kavossian, Elham, Aghadavod, Esmat, Bahmani, Fereshteh, Ostadmohammadi, Vahidreza, Kia, Mersedeh, Eftekhar, Tahereh, Ayati, Elnaz, Mahdavinia, Mostafa, Asemi, Zatollah
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 14.05.2019
• Subjects: Endocrinology; hormonal profiles; inflammatory markers; melatonin; oxidative stress; polycystic ovary syndrome; hormonal profiles; inflammatory markers; melatonin; oxidative stress; polycystic ovary syndrome
• ISSN: 1664-2392; 1664-2392
• DOI: 10.3389/fendo.2019.00273

The aim of the current study was to evaluate the effect of melatonin administration on clinical, hormonal, inflammatory, and genetic parameters in women with polycystic ovarian syndrome (PCOS). The present randomized, double-blinded, placebo-controlled clinical trial was conducted among 56 patients with PCOS, aged 18-40 years old. Subjects were randomly allocated to take either 5 mg melatonin supplements ( = 28) or placebo ( = 28) twice a day for 12 weeks. Melatonin administration significantly reduced hirsutism (β -0.47; 95% CI, -0.86, -0.09; = 0.01), serum total testosterone (β -0.11 ng/mL; 95% CI, -0.21, -0.02; = 0.01), high-sensitivity C-reactive protein (hs-CRP) (β -0.61 mg/L; 95% CI, -0.95, -0.26; = 0.001), and plasma malondialdehyde (MDA) levels (β -0.25 μmol/L; 95% CI, -0.38, -0.11; < 0.001), and significantly increased plasma total antioxidant capacity (TAC) levels (β 106.07 mmol/L; 95% CI, 62.87, 149.28; < 0.001) and total glutathione (GSH) (β 81.05 μmol/L; 95% CI, 36.08, 126.03; = 0.001) compared with the placebo. Moreover, melatonin supplementation downregulated gene expression of interleukin-1 (IL-1) ( = 0.03) and tumor necrosis factor alpha (TNF-α) ( = 0.01) compared with the placebo. Overall, melatonin administration for 12 weeks to women with PCOS significantly reduced hirsutism, total testosterone, hs-CRP, and MDA, while increasing TAC and GSH levels. In addition, melatonin administration reduced gene expression of IL-1 and TNF-α. www.irct.ir, identifier IRCT2017082733941N9, Available online at: https://www.irct.ir/trial/26051.